Following optimisation of dosage and exposure time in vitro, in vivo studies will assess the pharmacokinetics, therapeutic efficacy, and systemic safety of exogenously administered IL-37 and IL-38 in RA animal models (43, 44). Here, IL37 is linked to rheumatoid arthritis.